BGI Genomics Co Ltd (300676) — Cash Flow-to-Debt Ratio
BGI Genomics Co Ltd (300676) has a Cash Flow-to-Debt Ratio of 0.00x as of September 2025, meaning its operating cash flow of CN¥-3.08 Million could theoretically repay 0% of its total liabilities (CN¥2.93 Billion) in one year. See BGI Genomics Co Ltd (300676) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
BGI Genomics Co Ltd Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for BGI Genomics Co Ltd across 14 annual periods. For the full cash flow conversion analysis, see 300676 cash flow metrics.
Annual Cash Flow-to-Debt Ratio for BGI Genomics Co Ltd (2012–2025)
Year-by-year debt coverage analysis for BGI Genomics Co Ltd. Check how high is BGI Genomics Co Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.02x | CN¥-63.21 Million | CN¥3.14 Billion | ▼ -168.8% |
| 2024 | 0.03x | CN¥95.72 Million | CN¥3.27 Billion | ▼ -74.2% |
| 2023 | 0.11x | CN¥408.77 Million | CN¥3.61 Billion | ▲ +260.3% |
| 2022 | 0.03x | CN¥130.88 Million | CN¥4.16 Billion | ▼ -93.9% |
| 2021 | 0.51x | CN¥2.48 Billion | CN¥4.81 Billion | ▼ -24.0% |
| 2020 | 0.68x | CN¥3.60 Billion | CN¥5.32 Billion | ▲ +357.7% |
| 2019 | 0.15x | CN¥224.25 Million | CN¥1.52 Billion | ▲ +908.7% |
| 2018 | 0.01x | CN¥14.69 Million | CN¥1.00 Billion | ▼ -94.9% |
| 2017 | 0.29x | CN¥243.66 Million | CN¥853.88 Million | ▼ -5.2% |
| 2016 | 0.30x | CN¥234.07 Million | CN¥777.52 Million | ▼ -32.1% |
| 2015 | 0.44x | CN¥328.68 Million | CN¥741.37 Million | ▲ +3268.0% |
| 2014 | -0.01x | CN¥-8.16 Million | CN¥583.40 Million | ▼ -134.3% |
| 2013 | 0.04x | CN¥36.70 Million | CN¥899.46 Million | ▼ -52.0% |
| 2012 | 0.08x | CN¥72.49 Million | CN¥853.31 Million | — |